Previous close | 330.00 |
Open | 331.60 |
Bid | 332.90 x N/A |
Ask | 340.00 x N/A |
Day's range | 330.43 - 334.35 |
52-week range | 306.80 - 357.65 |
Volume | |
Avg. volume | 26,363,187 |
Market cap | 30.42B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 30.28 |
EPS (TTM) | 0.11 |
Earnings date | 29 Feb 2024 |
Forward dividend & yield | 0.06 (1.82%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | 362.14 |
AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.
Pfizer (PFE) plans to sell some shares of consumer healthcare firm Haleon (HLN), which it owns, to bring down its stake from 32% to 24%.